BioPharmSignal logoBioPharmSignal

Company Profile

Eledon Pharmaceuticals, Inc. Stock Price, News & Catalysts

Ticker:
ELDN
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

3.77 USD (+0.53%)

Close

Last updated: August 12, 2026

272M USD

Market cap

Why the stock is moving

The latest monitored company update is “Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights.” The corresponding closing-price reaction is not yet available.

Company overview

Transplant Immunology Company

Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens.

Tegoprubart

Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving other immune functions.

Kidney and Islet Transplantation

Clinical programs include kidney transplantation and an investigator-led islet-cell transplant study in people with high-risk type 1 diabetes, where insulin independence has been observed.

Broader Organ Transplantation

FDA Orphan Drug designation in liver transplantation adds another potential setting for tegoprubart beyond kidney and islet-cell replacement.

Future catalysts

  • Initiation of the global Phase 3 kidney-transplant study of tegoprubart in late 2026.

Recent news

  1. 01

    Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  2. 02

    Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

  3. 03

    Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

  4. 04

    Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

  5. 05

    Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

PPBT

Purple Biotech

QTTB

QTTB

CNTB

Connect Biopharma Holdings Limited

LABP

Landos Biopharma

EQ

Equillium, Inc.

TLSA

Tiziana Life Sciences

ADIL

Adial Pharmaceuticals

ASLN

ASLAN Pharmaceuticals

Frequently Asked Questions

What is the current stock price of Eledon Pharmaceuticals, Inc. (ELDN)?

Eledon Pharmaceuticals, Inc. (ELDN) most recently closed at 3.77 USD, a +0.53% move versus the previous session.

What is the market cap of Eledon Pharmaceuticals, Inc. (ELDN)?

Eledon Pharmaceuticals, Inc. currently has a market capitalization of 272M USD on BioPharmSignal.

What does Eledon Pharmaceuticals, Inc. do?

Transplant Immunology Company Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens. Tegoprubart Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving other immune...

On which exchange is ELDN stock listed?

Eledon Pharmaceuticals, Inc. (ELDN) is associated with NASDAQ, United States, Biopharma.

What is Transplant?

Initiation of the global Phase 3 kidney-transplant study of tegoprubart in late 2026.

Which conditions is Eledon Pharmaceuticals, Inc. targeting with Transplant?

Eledon Pharmaceuticals, Inc. is associated with immunology, diabetes based on its company overview and current catalyst commentary.

How does Eledon Pharmaceuticals, Inc. describe recent progress with Transplant?

Initiation of the global Phase 3 kidney-transplant study of tegoprubart in late 2026.

What is Immunology?

Transplant Immunology Company Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens.